(Q37996072)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

New and emerging treatments for Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Clive Ballard

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Anne Corbett

series ordinal

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

23 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

147-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease.

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Necropsy evidence of central cholinergic deficits in senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Meta-analysis of six-month memantine trials in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Secretase inhibitors and modulators for Alzheimer's disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Emerging and potential therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

A feasibility and tolerability study of lithium in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Hope in Alzheimer's fight emerges from unexpected places.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

21 January 2018

Dimebon disappointment

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Neuroprotection by tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Cognitive training for early-stage Alzheimer's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: Randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Putting brain training to the test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Exercise training increases size of hippocampus and improves memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Effects of aerobic exercise on mild cognitive impairment: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.675327

10.1517/14728214.2012.675327

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22439621%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference